Literature DB >> 15560045

Liver disease in cystic fibrosis.

K D Flora1, K G Benner.   

Abstract

CF is a common hereditary disorder of ion transport, with increasing numbers of patients surviving beyond childhood and developing manifestations of hepatobiliary involvement. Inspissated secretions within the biliary tree result in obstruction and periductular inflammation that eventually progresses to focal and then multilobular cirrhosis. Fatty infiltration of the liver and hepatomegaly is common. Variceal hemorrhage and other findings of portal hypertension may be the initial presentation. At present, therapy with high-dose ursodeoxycholic acid should be considered standard, as it has been shown repeatedly to reduce the injurious effects of the cholestasis. Liver transplantation has been successfully performed on those with advanced disease and adequate pulmonary function. Innovative therapies for CF, including gene transfer, appear promising in preliminary studies, offering hope that earlier intervention in the course of hepatobiliary CF may soon be possible.

Entities:  

Mesh:

Year:  1998        PMID: 15560045     DOI: 10.1016/s1089-3261(05)70363-9

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  3 in total

1.  Unexpected diagnosis of cystic fibrosis at liver biopsy: a report of four pediatric cases.

Authors:  Sophie Collardeau-Frachon; Raymonde Bouvier; Catherine Le Gall; Christine Rivet; Faiza Cabet; Gabriel Bellon; Alain Lachaux; Jean-Yves Scoazec
Journal:  Virchows Arch       Date:  2007-06-07       Impact factor: 4.064

2.  The Peter Pan paradigm.

Authors:  J Craig Cohen; Janet E Larson
Journal:  Theor Biol Med Model       Date:  2008-01-08       Impact factor: 2.432

3.  Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation.

Authors:  Fan Yang; Xiaowen Tang; Lili Ding; Yue Zhou; Qiaoling Yang; Junting Gong; Guangyun Wang; Zhengtao Wang; Li Yang
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.